P-gp/BCRP-IN-3
P-gp/BCRP-IN-3 is a dual-target inhibitor that acts on P-gp (ABCB1) and BCRP (ABCG2) transporters. P-gp/BCRP-IN-3 directly binds to both transporters, blocks efflux function without affecting protein expression, and restores intracellular accumulation of chemotherapeutic substrates. P-gp/BCRP-IN-3 enhances tumor accumulation and antitumor activity of Mitoxantrone (HY-13502) in colorectal cancer xenograft models. P-gp/BCRP-IN-3 is applicable for cancer-related research.
For research use only. We do not sell to patients.
- Formula: C44H37FN6O4
- Molecular Weight:732.80
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
P-gp/BCRP-IN-3 (Ib18) (5 μM; 48 h) is identified as a non-cytotoxic dual P-gp/BCRP resistance reversal agent, exhibiting potent BCRP inhibitory activity (RFBCRP = 2664.2) and favorable P-gp inhibitory activity (RFP-gp = 87.8) in MCF-7/ADR and HCT116/ABCG2 cells[1].
P-gp/BCRP-IN-3 (1-10 μM; 4 h) restores intracellular substrate accumulation in MCF-7/ADR and HCT116/ABCG2 cells by directly binding to P-gp/BCRP[1].
P-gp/BCRP-IN-3 (5 μM; 12 h) sensitizes drug-resistant cancer cells in MCF-7/ADR and HCT116/ABCG2 cells without broadly altering stress response pathways, and its reversal effect is achieved through functional inhibition rather than transcriptional perturbation[1].
P‑gp/BCRP‑IN‑3 (1‑10 μM; 48 h) does not produce its P‑gp/BCRP reversal activity via inhibiting protein synthesis or promoting protein degradation in MCF‑7/ADR and HCT116/ABCG2 cells[1].
P-gp/BCRP-IN-3 (1-5 μM; 30 min) directly binds to P-gp and BCRP, forming stable ligand-protein complexes, thereby inhibiting the function of efflux transporters in MCF-7/ADR and HCT116/ABCG2 cells[1].
P-gp/BCRP-IN-3 forms a stable dual binding with P-gp and BCRP, adopting an L-shaped conformation in both transporters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7/ADR and HCT116/ABCG2
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Exhibited a reversal fold against BCRP (RF_BCRP) of 2664.2.
Retained P-gp inhibitory activity (RF_P-gp) of 87.8.
-
Cell Line:MCF-7/ADR and HCT116/ABCG2
-
Concentration:1, 5, 10 μM
-
Incubation Time:48 h
-
Result:Did not produce substantial changes in P-gp or BCRP protein levels relative to the control group.
Variations in expression at 10 μM remained below 5%.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 4 weeks old, inoculated with HCT116/ABCG2 cells (5 × 107 cells/0.2 mL)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 2 days; 14 days
-
Result:Inhibited tumor growth in combination with Mitoxantrone, with a significant reduction in tumor volume over seven doses.
Did not affect general condition or cause obvious toxicity at 10 mg/kg, with body weight gain slightly greater than control.
Showed organ morphology, organ indices, and hematological parameters comparable to control.
Showed normal tissue morphology in all organs with no additional damage in combination.
Increased mitoxantrone accumulation in tumor tissue by approximately 1.3-fold and reduced mitoxantrone levels in normal tissues by 5% to 21%.
Chemical Information
-
Molecular Weight 732.80
-
Formula C44H37FN6O4
-
SMILES
CC(C=C1)=C(NC2=NC=CC(C3=CC=C(F)C=C3)=N2)C=C1C(NC(C=C4)=CC=C4C(C=C5)=CC6=C5NC(C(N(CC7)CC8=C7C=C(OC)C(OC)=C8)=O)=C6)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)